Synonym
Ro 04-5595 hydrochloride; Ro04-5595 HCl; Ro 04-5595; Ro-04-5595; Ro04-5595; Ro 045595; Ro-045595; Ro045595;
IUPAC/Chemical Name
1-[2-(4-Chlorophenyl)ethyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol hydrochloride
InChi Key
NVIPBLQAFKRFSZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H22ClNO2.ClH/c1-21-10-9-14-11-19(23-2)18(22)12-16(14)17(21)8-5-13-3-6-15(20)7-4-13;/h3-4,6-7,11-12,17,22H,5,8-10H2,1-2H3;1H
SMILES Code
OC1=CC2=C(C=C1OC)CCN(C)C2CCC3=CC=C(Cl)C=C3.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>3 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Ro 04-5595 has an EC 50 of 186 ± 32 nmol/L. Ro 04-5595 was predicted to bind the EVT-101 binding site. Ro 04-5595 hydrochloride is a selective antagonist for GluN2B containing NMDA receptors (Ki = 31 nM).
In vitro activity:
This study used primary cultures from chicken embryo forebrain, expressing native GluN2B-containing NMDA receptors. Ro 04-5595 had an EC 50 of 186 ± 32 nmol/L and was predicted to bind the EVT-101 binding site, not the ifenprodil-binding site.
Reference: Pharmacol Res Perspect. 2019 May 30;7(3):e00480. https://pubmed.ncbi.nlm.nih.gov/31164987/
In vivo activity:
To be determined
Preparing Stock Solutions
The following data is based on the
product
molecular weight
368.30
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Fjelldal MF, Freyd T, Evenseth LM, Sylte I, Ring A, Paulsen RE. Exploring the overlapping binding sites of ifenprodil and EVT-101 in GluN2B-containing NMDA receptors using novel chicken embryo forebrain cultures and molecular modeling. Pharmacol Res Perspect. 2019 May 30;7(3):e00480. doi: 10.1002/prp2.480. PMID: 31164987; PMCID: PMC6543015.
2. Bergeron S, Rompré PP. Blockade of ventral midbrain NMDA receptors enhances brain stimulation reward: a preferential role for GluN2A subunits. Eur Neuropsychopharmacol. 2013 Nov;23(11):1623-35. doi: 10.1016/j.euroneuro.2012.12.005. Epub 2013 Jan 23. PMID: 23352316.
In vitro protocol:
1. Fjelldal MF, Freyd T, Evenseth LM, Sylte I, Ring A, Paulsen RE. Exploring the overlapping binding sites of ifenprodil and EVT-101 in GluN2B-containing NMDA receptors using novel chicken embryo forebrain cultures and molecular modeling. Pharmacol Res Perspect. 2019 May 30;7(3):e00480. doi: 10.1002/prp2.480. PMID: 31164987; PMCID: PMC6543015.
2. Bergeron S, Rompré PP. Blockade of ventral midbrain NMDA receptors enhances brain stimulation reward: a preferential role for GluN2A subunits. Eur Neuropsychopharmacol. 2013 Nov;23(11):1623-35. doi: 10.1016/j.euroneuro.2012.12.005. Epub 2013 Jan 23. PMID: 23352316.
In vivo protocol:
To be determined
1: Neyama H, Dozono N, Ueda H. NR2A-NMDA Receptor Blockade Reverses the Lack of Morphine Analgesia Without Affecting Chronic Pain Status in a Fibromyalgia-Like Mouse Model. J Pharmacol Exp Ther. 2020 Apr;373(1):103-112. doi: 10.1124/jpet.119.262642. Epub 2020 Jan 15. PMID: 31941720.
2: Fjelldal MF, Freyd T, Evenseth LM, Sylte I, Ring A, Paulsen RE. Exploring the overlapping binding sites of ifenprodil and EVT-101 in GluN2B-containing NMDA receptors using novel chicken embryo forebrain cultures and molecular modeling. Pharmacol Res Perspect. 2019 May 30;7(3):e00480. doi: 10.1002/prp2.480. PMID: 31164987; PMCID: PMC6543015.
3: Li MH, Underhill SM, Reed C, Phillips TJ, Amara SG, Ingram SL. Amphetamine and Methamphetamine Increase NMDAR-GluN2B Synaptic Currents in Midbrain Dopamine Neurons. Neuropsychopharmacology. 2017 Jun;42(7):1539-1547. doi: 10.1038/npp.2016.278. Epub 2016 Dec 15. PMID: 27976681; PMCID: PMC5436114.
4: Bergeron S, Rompré PP. Blockade of ventral midbrain NMDA receptors enhances brain stimulation reward: a preferential role for GluN2A subunits. Eur Neuropsychopharmacol. 2013 Nov;23(11):1623-35. doi: 10.1016/j.euroneuro.2012.12.005. Epub 2013 Jan 23. PMID: 23352316.
5: Mutel V, Buchy D, Klingelschmidt A, Messer J, Bleuel Z, Kemp JA, Richards JG. In vitro binding properties in rat brain of [3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits. J Neurochem. 1998 May;70(5):2147-55. doi: 10.1046/j.1471-4159.1998.70052147.x. PMID: 9572302.
